Form 4: Director Mazelsky Acquires DENTSPLY SIRONA Phantom Stock

DENTSPLY SIRONA Director Jonathan Jay Mazelsky acquired 2,386.165 shares of phantom stock as part of his deferred compensation plan.

Summary

• Jonathan Jay Mazelsky, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired phantom stock.
• The transaction, dated September 30, 2025, involved the acquisition of 2,386.165 shares of phantom stock.
• Each phantom stock share is the economic equivalent of one common stock share.
• The phantom stock becomes payable in common stock upon the reporting person's termination of service as a director.
• The acquisition price for the phantom stock was $12.57 per share.
• Following this transaction, Mazelsky beneficially owns a total of 11,620.2024 phantom stock shares.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock by a director, particularly as part of a deferred compensation plan, generally signals alignment of interests with shareholders and confidence in the company's long-term prospects. It is a routine compensation event but still a positive indicator of insider commitment.

Positives

• Director Jonathan Jay Mazelsky increased his beneficial ownership in DENTSPLY SIRONA Inc. through the acquisition of 2,386.165 phantom stock shares.
• The acquisition is part of a deferred compensation plan, which aligns director interests with long-term shareholder value and company performance.

Future Outlook

The phantom stock acquired by the director will become payable in common stock upon his termination of service, indicating a long-term retention and incentive mechanism.

Industry Context

Deferred compensation plans involving equity-linked instruments like phantom stock are a common practice in many public companies across various industries, including healthcare and dental technology, to incentivize and retain directors and executives by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• Deferred compensation plans for directors, often involving equity-based awards such as phantom stock, are standard practice across publicly traded companies. For instance, companies like Align Technology (ALGN) and Henry Schein (HSIC), also in the dental and medical device sectors, utilize various forms of equity compensation to align director and executive interests with shareholder value.
• The specific valuation of $12.57 per phantom stock share and the number of shares awarded are consistent with typical compensation structures, reflecting DENTSPLY SIRONA's compensation policies for its non-employee directors.

Related Party Transactions

• The acquisition of phantom stock by a director from the company is a related party transaction, structured as part of the director's deferred compensation plan.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it indicates a director's continued commitment and alignment with the company's long-term performance.

Next Steps

• The phantom stock will be converted into common stock and paid out upon the reporting person's termination of service as a director.

Key Dates

Recommendation

This filing reports a routine insider transaction where a director acquired phantom stock as part of a deferred compensation plan. While this indicates alignment of interests and confidence in the company's long-term prospects, it is not a significant catalyst for a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for investors already in the stock, as it suggests continued commitment from leadership.

Keywords

DENTSPLY SIRONA, XRAY, Jonathan Jay Mazelsky, Director, Phantom Stock, Deferred Compensation, Insider Transaction, SEC Form 4